JP7016865B2 - Il-10およびインスリンを安定的に発現する遺伝子改変された細菌 - Google Patents

Il-10およびインスリンを安定的に発現する遺伝子改変された細菌 Download PDF

Info

Publication number
JP7016865B2
JP7016865B2 JP2019512264A JP2019512264A JP7016865B2 JP 7016865 B2 JP7016865 B2 JP 7016865B2 JP 2019512264 A JP2019512264 A JP 2019512264A JP 2019512264 A JP2019512264 A JP 2019512264A JP 7016865 B2 JP7016865 B2 JP 7016865B2
Authority
JP
Japan
Prior art keywords
lab
gene
nucleic acid
subject
lactobacillus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2019512264A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019526262A (ja
JP2019526262A5 (cg-RX-API-DMAC7.html
Inventor
ロティエ,ピーター
ステイドラー,ロタール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intrexon Actobiotics NV
Original Assignee
Intrexon Actobiotics NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrexon Actobiotics NV filed Critical Intrexon Actobiotics NV
Publication of JP2019526262A publication Critical patent/JP2019526262A/ja
Publication of JP2019526262A5 publication Critical patent/JP2019526262A5/ja
Priority to JP2022010063A priority Critical patent/JP2022061035A/ja
Application granted granted Critical
Publication of JP7016865B2 publication Critical patent/JP7016865B2/ja
Priority to JP2024009123A priority patent/JP2024047590A/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019512264A 2016-09-02 2017-09-02 Il-10およびインスリンを安定的に発現する遺伝子改変された細菌 Expired - Fee Related JP7016865B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022010063A JP2022061035A (ja) 2016-09-02 2022-01-26 Il-10およびインスリンを安定的に発現する遺伝子改変された細菌
JP2024009123A JP2024047590A (ja) 2016-09-02 2024-01-25 Il-10およびインスリンを安定的に発現する遺伝子改変された細菌

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662383079P 2016-09-02 2016-09-02
US62/383,079 2016-09-02
PCT/IB2017/055287 WO2018042390A1 (en) 2016-09-02 2017-09-02 Genetically modified bacteria stably expressing il-10 and insulin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022010063A Division JP2022061035A (ja) 2016-09-02 2022-01-26 Il-10およびインスリンを安定的に発現する遺伝子改変された細菌

Publications (3)

Publication Number Publication Date
JP2019526262A JP2019526262A (ja) 2019-09-19
JP2019526262A5 JP2019526262A5 (cg-RX-API-DMAC7.html) 2020-10-15
JP7016865B2 true JP7016865B2 (ja) 2022-03-03

Family

ID=60120085

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019512264A Expired - Fee Related JP7016865B2 (ja) 2016-09-02 2017-09-02 Il-10およびインスリンを安定的に発現する遺伝子改変された細菌
JP2022010063A Pending JP2022061035A (ja) 2016-09-02 2022-01-26 Il-10およびインスリンを安定的に発現する遺伝子改変された細菌
JP2024009123A Pending JP2024047590A (ja) 2016-09-02 2024-01-25 Il-10およびインスリンを安定的に発現する遺伝子改変された細菌

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022010063A Pending JP2022061035A (ja) 2016-09-02 2022-01-26 Il-10およびインスリンを安定的に発現する遺伝子改変された細菌
JP2024009123A Pending JP2024047590A (ja) 2016-09-02 2024-01-25 Il-10およびインスリンを安定的に発現する遺伝子改変された細菌

Country Status (8)

Country Link
US (3) US10858663B2 (cg-RX-API-DMAC7.html)
EP (1) EP3506932B1 (cg-RX-API-DMAC7.html)
JP (3) JP7016865B2 (cg-RX-API-DMAC7.html)
CN (2) CN118813511A (cg-RX-API-DMAC7.html)
AU (1) AU2017319707B2 (cg-RX-API-DMAC7.html)
CA (1) CA3035151A1 (cg-RX-API-DMAC7.html)
RU (1) RU2768027C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018042390A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10858663B2 (en) * 2016-09-02 2020-12-08 Intrexon Actobiotics N.V. Genetically modified bacteria stably expressing IL-10 and insulin
KR102469701B1 (ko) 2016-09-13 2022-11-22 인트랙슨 액토바이오틱스 엔.브이. 점막부착성 미생물
EP4582440A3 (en) * 2018-12-21 2025-10-08 The Regents of the University of California Il-10-containing vaccines and uses thereof
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を予防するための方法および組成物
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
WO2024146463A1 (zh) * 2023-01-03 2024-07-11 深圳先进技术研究院 分泌白介素-10的细菌
CN116726158A (zh) * 2023-04-24 2023-09-12 中国医学科学院医学生物学研究所 一种多表位1型糖尿病疫苗及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013041673A1 (en) 2011-09-23 2013-03-28 Actogenix Nv Modified gram positive bacteria and uses thereof
JP2014518062A (ja) 2011-06-01 2014-07-28 アクトジェニックス・エヌブイ 細菌のポリシストロン性発現系

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB227835A (en) 1924-01-15 1925-04-09 Harry Odell Improvements in feeding mechanism for embossing and other printing presses
US4919918A (en) 1988-03-14 1990-04-24 Spectrum Consumer Products Co., Inc. Non-alcoholic mouthwash
US5972685A (en) 1988-07-21 1999-10-26 Iowa State University Research Foundation, Inc. Oral administration of coprostanol producing microorganisms to humans to decrease plasma cholesterol concentration
GB9126306D0 (en) 1991-12-11 1992-02-12 Unilever Plc Mouthwash compositions
EP0628083A1 (en) 1992-02-27 1994-12-14 Microbial Technics Limited Heterologous gene expression in lactococcus, and the expression products therefrom
US5223285A (en) 1992-03-31 1993-06-29 Abbott Laboratories Nutritional product for pulmonary patients
US5700782A (en) 1993-05-28 1997-12-23 Abbott Laboratories Enteral nutritional product
WO1996032486A1 (en) 1995-04-11 1996-10-17 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Method for the construction of vectors for lactic acid bacteria like lactobacillus such that the bacteria can efficiently express, secrete and display proteins at the surface
US5695746A (en) 1995-07-28 1997-12-09 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Liquid dentifrice with mouthwash fresh taste
US6348187B1 (en) 1996-01-24 2002-02-19 Warner-Lambert Company Peroxide/essential oils containing mouthwash compositions and two-part mouthwash systems
GB9611364D0 (en) 1996-05-31 1996-08-07 Smithkline Beecham Plc Composition
ES2197364T3 (es) 1996-09-18 2004-01-01 Erling Johansen Baño bucal comprendiendo iones de calcio y fosfato en solucion sobresaturada.
US5869118A (en) 1996-11-13 1999-02-09 Abbott Laboratories Gellan gum to improve physical stability of liquid nutritional products
US6171611B1 (en) 1997-11-12 2001-01-09 Dante J. Picciano Iodine-containing nasal moisturizing saline and mouthwash solutions
US5897872A (en) 1997-11-12 1999-04-27 Picciano; Dante J. Iodine-containing nasal moisturizing saline solution
WO2000018377A1 (en) 1998-09-28 2000-04-06 Warner-Lambert Company Enteric and colonic delivery using hpmc capsules
WO2000022909A2 (en) 1998-10-19 2000-04-27 Biotech Australia Pty. Limited Systems for oral delivery
CA2446776C (en) 2001-05-03 2011-07-12 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Self-containing lactococcus strain
US20040043003A1 (en) * 2002-01-31 2004-03-04 Wei Chen Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions
AU2003247881A1 (en) 2002-07-08 2004-01-23 Joe S. Wilkins Jr. Antibacterial formulations
WO2004056850A2 (en) * 2002-12-19 2004-07-08 Vib Vzw Mutant proteins showing increased secretion
DK2119450T3 (da) 2005-11-29 2013-05-06 Actogenix Nv Induktion af mucosal tolerance over for pankreatisk ø-beta-celle-autoantigener
CN101605900B (zh) * 2007-01-12 2014-04-23 阿克图杰尼斯公司 乳球菌启动子和其用途
BRPI0807857A2 (pt) * 2007-01-25 2014-05-27 Actogenix Nv Tratamento de doença imune por meio de distribuição através da mucosa de antígenos.
NZ580006A (en) 2007-03-28 2012-03-30 Alimentary Health Ltd Probiotic bifidobacterium strain 41387
JP5572972B2 (ja) * 2009-03-16 2014-08-20 Jnc株式会社 インスリン分泌促進剤などの薬物のスクリーニング方法
ES2425385T3 (es) 2009-04-30 2013-10-15 Actogenix N.V. Crioprotectores para la liofilización de las bacterias de ácido láctico
HUE038830T2 (hu) * 2011-09-23 2018-11-28 Intrexon Actobiotics Nv Módosított gram-pozitív baktériumok és alkalmazásaik
US10858663B2 (en) * 2016-09-02 2020-12-08 Intrexon Actobiotics N.V. Genetically modified bacteria stably expressing IL-10 and insulin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014518062A (ja) 2011-06-01 2014-07-28 アクトジェニックス・エヌブイ 細菌のポリシストロン性発現系
WO2013041673A1 (en) 2011-09-23 2013-03-28 Actogenix Nv Modified gram positive bacteria and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Current Opinion in Microbiology,2013年07月11日,Vol. 16, No. 3,p. 278-283
The Journal of Clinical Investigation,2012年04月,Vol. 122, No. 5,p. 1717-1725

Also Published As

Publication number Publication date
CN109843320A (zh) 2019-06-04
US20190292551A1 (en) 2019-09-26
US11549118B2 (en) 2023-01-10
EP3506932A1 (en) 2019-07-10
RU2019104948A (ru) 2020-10-02
US20230348918A1 (en) 2023-11-02
RU2019104948A3 (cg-RX-API-DMAC7.html) 2020-12-23
US12359210B2 (en) 2025-07-15
JP2022061035A (ja) 2022-04-15
EP3506932B1 (en) 2025-06-25
JP2019526262A (ja) 2019-09-19
US20210180072A1 (en) 2021-06-17
RU2768027C2 (ru) 2022-03-23
US10858663B2 (en) 2020-12-08
AU2017319707B2 (en) 2023-11-09
JP2024047590A (ja) 2024-04-05
AU2017319707A1 (en) 2019-03-07
CN118813511A (zh) 2024-10-22
WO2018042390A1 (en) 2018-03-08
CA3035151A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
US12246046B2 (en) Compositions and methods for the treatment of type 1 diabetes
US12359210B2 (en) Genetically modified bacteria stably expressing IL-10 and insulin
US20220340621A1 (en) Treatment of celiac disease
HK40065260A (en) Compositions and methods for the treatment of type 1 diabetes
HK40065260B (en) Compositions and methods for the treatment of type 1 diabetes
HK1262225B (en) Compositions and methods for the treatment of type 1 diabetes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200826

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200826

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210921

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220126

R150 Certificate of patent or registration of utility model

Ref document number: 7016865

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees